DK3494115T3 - N-(phenylsulfonyl)benzamidderivater som bcl-2-hæmmere - Google Patents

N-(phenylsulfonyl)benzamidderivater som bcl-2-hæmmere Download PDF

Info

Publication number: DK3494115T3
Authority: DK; Denmark
Prior art keywords: phenylsulphonyl; bcl; inhibitors; benzamide derivatives; benzamide
Prior art date: 2016-08-05

Application number

DK17754889.8T

Other languages

English (en)

Inventor

Jianyong Chen

Shaomeng Wang

Original Assignee

Univ Michigan Regents

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-05

Filing date

2017-08-04

Publication date

2021-01-18

2017-08-04 Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents

2021-01-18 Application granted granted Critical

2021-01-18 Publication of DK3494115T3 publication Critical patent/DK3494115T3/da

Links

239000012664 BCL-2-inhibitor Substances 0.000 title 1
229940123711 Bcl2 inhibitor Drugs 0.000 title 1
ZBGWAJQUDSCDPB-UHFFFAOYSA-N n-(benzenesulfonyl)benzamide Chemical class C=1C=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1 ZBGWAJQUDSCDPB-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)

DK17754889.8T 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamidderivater som bcl-2-hæmmere DK3494115T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662371504P	2016-08-05	2016-08-05
US201762454101P	2017-02-03	2017-02-03
PCT/US2017/045428 WO2018027097A1 (en)	2016-08-05	2017-08-04	N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Publications (1)

Publication Number	Publication Date
DK3494115T3 true DK3494115T3 (da)	2021-01-18

Family

ID=59677319

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17754889.8T DK3494115T3 (da)	2016-08-05	2017-08-04	N-(phenylsulfonyl)benzamidderivater som bcl-2-hæmmere

Country Status (27)

Country	Link
US (3)	US10829488B2 (da)
EP (3)	EP4129999A1 (da)
JP (2)	JP6651180B2 (da)
KR (2)	KR102429704B1 (da)
CN (2)	CN110483501B (da)
AU (2)	AU2017305508B2 (da)
CA (1)	CA3031419C (da)
CY (1)	CY1123859T1 (da)
DK (1)	DK3494115T3 (da)
ES (1)	ES2849959T3 (da)
HR (1)	HRP20202073T1 (da)
HU (1)	HUE053414T2 (da)
IL (2)	IL264059B (da)
LT (1)	LT3494115T (da)
MX (2)	MX381588B (da)
MY (1)	MY199409A (da)
PE (1)	PE20190711A1 (da)
PH (1)	PH12019500231A1 (da)
PT (1)	PT3494115T (da)
RS (1)	RS61821B1 (da)
RU (2)	RU2744358C2 (da)
SA (1)	SA519401020B1 (da)
SG (2)	SG11201900135YA (da)
SI (1)	SI3494115T1 (da)
SM (1)	SMT202100025T1 (da)
WO (1)	WO2018027097A1 (da)
ZA (2)	ZA201900240B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3426655A1 (en) *	2016-03-10	2019-01-16	Assia Chemical Industries Ltd.	Solid state forms of venetoclax and processes for preparation of venetoclax
US10829488B2 (en) *	2016-08-05	2020-11-10	The Regents Of The University Of Michigan	N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
EP3565815B1 (en)	2017-01-07	2024-03-13	Fochon Pharmaceuticals, Ltd.	Compounds as bcl-2-selective apoptosis-inducing agents
EP3612531B1 (en) *	2017-04-18	2022-08-24	Shanghai Fochon Pharmaceutical Co., Ltd.	Apoptosis-inducing agents
SG11202009933WA (en)	2018-04-29	2020-11-27	Beigene Ltd	Bcl-2 INHIBITORS
BR112020018978A2 (pt) *	2018-07-31	2021-03-02	Ascentage Pharma (Suzhou) Co., Ltd.	produto de combinação que compreende um inibidor de bcl-2 e um inibidor de mdm2 e uso dos ditos inibidores na prevenção e/ou tratamento de câncer
CA3095699A1 (en) *	2018-07-31	2020-02-06	Ascentage Pharma (Suzhou) Co., Ltd.	Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN114522167A (zh) *	2018-07-31	2022-05-24	苏州亚盛药业有限公司	Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
US11554127B2 (en) *	2018-07-31	2023-01-17	Ascentage Pharma (Suzhou) Co., Ltd.	Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
WO2020103921A1 (en) *	2018-11-23	2020-05-28	Ascentage Pharma (Suzhou) Co., Ltd.	Pharmaceutical composition and use thereof
TWI770503B (zh) *	2019-05-13	2022-07-11	大陸商蘇州亞盛藥業有限公司	用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
CN112168830B (zh) *	2019-07-02	2022-01-25	苏州亚盛药业有限公司	一种含有mTOR抑制剂的药物组合及其应用
US12370197B2 (en) *	2019-07-31	2025-07-29	Ascentage Pharma (Suzhou) Co., Ltd.	Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
WO2021083135A1 (en)	2019-10-28	2021-05-06	Beigene, Ltd.	Bcl-2 INHIBITORS
US12287338B2 (en)	2019-11-27	2025-04-29	Ascentage Pharma (Suzhou) Co., Ltd.	Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
CN119097631A (zh) *	2019-12-03	2024-12-10	苏州亚盛药业有限公司	作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
TWI777321B (zh) *	2019-12-04	2022-09-11	大陸商蘇州亞盛藥業有限公司	藥物組合及其用途
JP7142173B2 (ja)	2019-12-06	2022-09-26	ロクソオンコロジー，インコーポレイテッド	ブルトン型チロシンキナーゼ阻害剤の投薬
WO2021175321A1 (en)	2020-03-06	2021-09-10	Ascentage Pharma (Suzhou) Co., Ltd.	Crystalline forms or amorphous forms of n- (phenyl sulfonyl) benzamide compounds or its salts or solvates
US20230128137A1 (en) *	2020-03-12	2023-04-27	Medshine Discovery Inc.	Benzo five-membered cyclic compound
IL296582A (en)	2020-04-15	2022-11-01	Beigene Ltd	bcl-2 inhibitor
WO2021227763A1 (en) *	2020-05-14	2021-11-18	Ascentage Pharma (Suzhou) Co., Ltd.	Hplc analysis method for n- (phenylsulfonyl) benzamide compound
WO2022002178A1 (en) *	2020-07-01	2022-01-06	Ascentage Pharma (Suzhou) Co., Ltd.	Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof
CN111537654B (zh) *	2020-07-07	2020-11-10	上海亚盛医药科技有限公司	N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
BR112023000320A2 (pt) *	2020-07-10	2023-01-31	Jiangsu Hengrui Pharmaceuticals Co Ltd	Derivado de sulfonilbenzamida e seu cojugado, método de preparação do mesmo e seu uso
CN114057728A (zh) *	2020-08-06	2022-02-18	北京诺诚健华医药科技有限公司	作为bcl-2抑制剂的杂环化合物
US20230301989A1 (en) *	2020-08-21	2023-09-28	Ascentage Pharma (Suzhou) Co., Ltd.	Compositions and methods for treating systemic lupus erythematosus
CN114073703B (zh) *	2020-08-21	2022-12-30	苏州亚盛药业有限公司	用于治疗非酒精性脂肪肝炎的组合物和方法
CN114533677A (zh) *	2020-11-25	2022-05-27	苏州亚盛药业有限公司	固体分散体、制剂、其制备方法及其应用
US20240316069A1 (en) *	2020-12-28	2024-09-26	Ascentage Pharma (Suzhou) Co., Ltd.	Methods of treating multiple sclerosis
WO2022161496A1 (en) *	2021-02-01	2022-08-04	Ascentage Pharma (Suzhou) Co., Ltd.	Sulfonyl benzamide derivatives as bcl-2 inhibitors
WO2022216942A1 (en)	2021-04-07	2022-10-13	Dana-Farber Cancer Institute, Inc.	Compositions and methods for the treatment of cancer
CN117957018A (zh)	2021-08-02	2024-04-30	苏州亚盛药业有限公司	一种药物组合及其用途
CA3238433A1 (en) *	2021-12-06	2023-06-15	Xingguo LIU	Anti-apoptotic protein bcl-2 inhibitor, pharmaceutical composition and uses thereof
CN115260191B (zh) *	2022-09-29	2022-12-27	上海睿跃生物科技有限公司	哌啶类化合物及其制备方法和应用
EP4421075A1 (en) *	2023-02-27	2024-08-28	KRKA, d.d., Novo mesto	Process for the preparation of venetoclax and intermediates used therein
JP2026510567A (ja)	2023-03-03	2026-04-08	アイオンクチュラ・ソシエテ・アノニム	血液悪性腫瘍の治療におけるロギノリシブ及びｂｃｌ－２阻害剤の組み合わせ

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1021343A (en)	1912-01-17	1912-03-26	M A N Mfg Company	Locking-clamp.
US5093330A (en)	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
US7767684B2 (en) *	2003-11-13	2010-08-03	Abbott Laboratories	Apoptosis promoters
WO2005049593A2 (en)	2003-11-13	2005-06-02	Abbott Laboratories	N-acylsulfonamide apoptosis promoters
US8624027B2 (en)	2005-05-12	2014-01-07	Abbvie Inc.	Combination therapy for treating cancer and diagnostic assays for use therein
JP5277168B2 (ja)	2006-09-05	2013-08-28	アボット・ラボラトリーズ	血小板過剰を治療するｂｃｌインヒビター
US20080199873A1 (en)	2006-12-04	2008-08-21	Anderson Mark G	Companion diagnostic assays for cancer therapy
UA108193C2 (uk) *	2008-12-04	2015-04-10		Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
DK2376480T3 (da)	2008-12-05	2016-09-12	Abbvie Inc	Sulfonamidderivater som bcl-2-selektive apoptoseinducerende midler til behandling af cancer og immunsygdomme
WO2010083442A1 (en)	2009-01-19	2010-07-22	Abbott Laboratories	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2012517241A (ja)	2009-02-11	2012-08-02	アボット・ラボラトリーズ	Ｂｃｌ−２ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物
US8546399B2 (en)	2009-05-26	2013-10-01	Abbvie Inc.	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) *	2009-05-26	2010-12-02	Abbott Laboratories	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) *	2010-05-26	2016-02-11	艾伯維有限公司	用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
CA3152557A1 (en)	2010-10-29	2012-05-03	Abbvie Inc.	Solid dispersions containing an apoptosis-inducing agent
PT2643322T (pt) *	2010-11-23	2017-11-13	Abbvie Inc	Sais e formas cristalinas de um agente indutor de apoptose
ES2603129T3 (es) *	2010-11-23	2017-02-23	Abbvie Ireland Unlimited Company	Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
EP4218572A1 (en)	2015-12-30	2023-08-02	Dexcom, Inc.	System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile
US10829488B2 (en) *	2016-08-05	2020-11-10	The Regents Of The University Of Michigan	N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

2017
- 2017-08-04 US US16/317,056 patent/US10829488B2/en active Active
- 2017-08-04 EP EP22179906.7A patent/EP4129999A1/en active Pending
- 2017-08-04 RU RU2020114660A patent/RU2744358C2/ru active
- 2017-08-04 CN CN201910626474.XA patent/CN110483501B/zh active Active
- 2017-08-04 MX MX2019001391A patent/MX381588B/es unknown
- 2017-08-04 ES ES17754889T patent/ES2849959T3/es active Active
- 2017-08-04 DK DK17754889.8T patent/DK3494115T3/da active
- 2017-08-04 CA CA3031419A patent/CA3031419C/en active Active
- 2017-08-04 PT PT177548898T patent/PT3494115T/pt unknown
- 2017-08-04 RS RS20201599A patent/RS61821B1/sr unknown
- 2017-08-04 SM SM20210025T patent/SMT202100025T1/it unknown
- 2017-08-04 HU HUE17754889A patent/HUE053414T2/hu unknown
- 2017-08-04 CN CN201780035965.6A patent/CN109311871B/zh active Active
- 2017-08-04 SG SG11201900135YA patent/SG11201900135YA/en unknown
- 2017-08-04 LT LTEP17754889.8T patent/LT3494115T/lt unknown
- 2017-08-04 AU AU2017305508A patent/AU2017305508B2/en active Active
- 2017-08-04 HR HRP20202073TT patent/HRP20202073T1/hr unknown
- 2017-08-04 RU RU2019105721A patent/RU2722560C1/ru active
- 2017-08-04 KR KR1020217026744A patent/KR102429704B1/ko active Active
- 2017-08-04 SG SG10201913643YA patent/SG10201913643YA/en unknown
- 2017-08-04 EP EP17754889.8A patent/EP3494115B1/en active Active
- 2017-08-04 KR KR1020197002744A patent/KR102376764B1/ko active Active
- 2017-08-04 MY MYPI2019000239A patent/MY199409A/en unknown
- 2017-08-04 SI SI201730535T patent/SI3494115T1/sl unknown
- 2017-08-04 EP EP19184604.7A patent/EP3569601B1/en active Active
- 2017-08-04 PE PE2019000335A patent/PE20190711A1/es unknown
- 2017-08-04 JP JP2019506191A patent/JP6651180B2/ja active Active
- 2017-08-04 WO PCT/US2017/045428 patent/WO2018027097A1/en not_active Ceased
2018
- 2018-08-01 US US16/051,816 patent/US10221174B2/en active Active
2019
- 2019-01-02 IL IL264059A patent/IL264059B/en active IP Right Grant
- 2019-01-14 ZA ZA2019/00240A patent/ZA201900240B/en unknown
- 2019-01-31 PH PH12019500231A patent/PH12019500231A1/en unknown
- 2019-01-31 MX MX2020013014A patent/MX2020013014A/es unknown
- 2019-02-04 SA SA519401020A patent/SA519401020B1/ar unknown
- 2019-07-23 JP JP2019135624A patent/JP7205903B2/ja active Active
- 2019-12-19 ZA ZA2019/08466A patent/ZA201908466B/en unknown
2020
- 2020-09-17 US US17/023,426 patent/US11718613B2/en active Active
2021
- 2021-01-15 CY CY20211100032T patent/CY1123859T1/el unknown
- 2021-04-06 AU AU2021202113A patent/AU2021202113B2/en active Active
- 2021-04-06 IL IL282099A patent/IL282099B/en unknown

Also Published As

Publication number	Publication date
RU2744358C2 (ru)	2021-03-05
KR102376764B1 (ko)	2022-03-18
ZA201908466B (en)	2020-05-27
CN110483501A (zh)	2019-11-22
EP3494115B1 (en)	2020-10-21
JP6651180B2 (ja)	2020-02-19
EP4129999A1 (en)	2023-02-08
IL264059B (en)	2021-05-31
SG10201913643YA (en)	2020-03-30
WO2018027097A1 (en)	2018-02-08
US11718613B2 (en)	2023-08-08
PE20190711A1 (es)	2019-05-17
RU2020114660A3 (da)	2020-09-15
EP3494115A1 (en)	2019-06-12
CY1123859T1 (el)	2022-05-27
PT3494115T (pt)	2021-01-15
MY199409A (en)	2023-10-25
HRP20202073T1 (hr)	2021-02-19
ZA201900240B (en)	2020-05-27
SG11201900135YA (en)	2019-02-27
IL282099A (en)	2021-05-31
SI3494115T1 (sl)	2021-02-26
NZ750100A (en)	2021-01-29
MX2020013014A (es)	2021-02-22
US10829488B2 (en)	2020-11-10
US20180354950A1 (en)	2018-12-13
PH12019500231A1 (en)	2019-07-29
RS61821B1 (sr)	2021-06-30
SMT202100025T1 (it)	2021-03-15
CN109311871B (zh)	2020-02-28
IL264059A (en)	2019-01-31
AU2017305508B2 (en)	2021-01-07
CA3031419C (en)	2021-08-24
EP3569601B1 (en)	2022-06-22
MX381588B (es)	2025-03-12
BR112019001666A2 (pt)	2019-05-28
ES2849959T3 (es)	2021-08-24
CN110483501B (zh)	2022-07-01
US10221174B2 (en)	2019-03-05
IL282099B (en)	2022-03-01
JP7205903B2 (ja)	2023-01-17
RU2020114660A (ru)	2020-06-19
RU2020134802A (ru)	2022-04-25
HUE053414T2 (hu)	2021-06-28
KR20190035710A (ko)	2019-04-03
US20190315739A1 (en)	2019-10-17
AU2021202113A1 (en)	2021-05-06
CA3031419A1 (en)	2018-02-08
US20210002277A1 (en)	2021-01-07
JP2019527705A (ja)	2019-10-03
SA519401020B1 (ar)	2022-03-16
EP3569601A3 (en)	2019-11-27
AU2021202113B2 (en)	2022-08-18
JP2020007311A (ja)	2020-01-16
KR20210107170A (ko)	2021-08-31
LT3494115T (lt)	2021-01-25
RU2722560C1 (ru)	2020-06-01
MX2019001391A (es)	2019-06-06
KR102429704B1 (ko)	2022-08-04
CN109311871A (zh)	2019-02-05
AU2017305508A1 (en)	2019-02-07
EP3569601A2 (en)	2019-11-20

Publication	Publication Date	Title
DK3494115T3 (da)	2021-01-18	N-(phenylsulfonyl)benzamidderivater som bcl-2-hæmmere
DK3986890T3 (da)	2023-12-18	Benzisoxazol-sulfonamid-derivater
DK3768674T3 (da)	2024-02-19	Aminopyrimidinderivater som ctps1-hæmmere
DK3697785T3 (da)	2023-04-03	Imidazo-pyridine forbindelser som pad-inhibitorer
DK3684767T3 (da)	2024-07-15	Heterocykliske forbindelser som pad-inhibitorer
DK3472165T3 (da)	2023-12-11	N-(substituererede-phenyl)-sulfonamidderivater som kinasehæmmere
DK3328849T5 (da)	2021-02-15	1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
DK3580220T3 (da)	2022-01-10	Aminotriazolpyridiner som kinasehæmmere
DK3054936T3 (da)	2024-01-15	4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer
DK3440076T3 (da)	2022-07-11	Heterocykliske amider, der kan anvendes som proteinmodulatorer
DK3442980T3 (da)	2021-08-30	Heterocykliske forbindelser som ret-kinase-hæmmere
DK3464271T3 (da)	2020-06-15	Pyrazolderivater som plasma-kallikreininhibitorer
DK3442947T3 (da)	2023-09-04	Aminsubstituerede aryl- eller heteroarylforbindelser som ehmt1- og ehmt2-hæmmere
DK3277681T3 (da)	2019-07-29	Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3562810T3 (da)	2023-07-24	Benzhydroxamsyre-derivater som selektive hdac6-inhibitorer
DK3105218T3 (da)	2019-11-04	Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da)	2019-10-14	Cyclopropylaminer som lsd1-inhibitorer
DK3313832T3 (da)	2021-04-19	3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK3687996T3 (da)	2022-01-10	Salte af pyrrolotriazinderivater anvendelige som tam-inhibitorer
DK3538528T3 (da)	2021-02-15	Pyrrolamider som alpha v-integrinhæmmere
DK3762368T3 (da)	2022-03-28	Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3704118T3 (da)	2022-03-14	Aminoimidazopyrazin som kinasehæmmere
DK3724165T3 (da)	2022-02-21	Nye benzamidderivater som PPAR-gamma-modulatorer
DK3700907T3 (da)	2022-05-30	Hidtil ukendte pyrazolo-pyrrolo-pyrimidindion-derivater som p2x3-inhibitorer
DK3670499T3 (da)	2022-01-03	Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)